Window Shopping: Rheumatoid Arthritis Biosimilars On Show At ACR
Executive Summary
Clinicians in the US can’t buy in to anti-TNF biosimilars yet, but wave of equivalence data featured at American College of Rheumatology meeting gives them a chance to evaluate products before they hit the market.
You may also be interested in...
JAK Inhibitors Start To Come Of Age In Rheumatoid Arthritis
Oral class has gotten off to slow start, but data for range of JAK inhibitors – including Lilly’s once-daily baricitinib – presented at American College of Rheumatology meeting are encouraging.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.